{"entity":{"id":"brenus-pharma","kind":"company","name":"Brenus Pharma","aka":[],"tldr":"Brenus Pharma makes an off-the-shelf immunotherapy from inactivated, specially prepared cancer cells, designed to teach the immune system to recognise bowel cancer that has spread.","summary":"Brenus Pharma, with offices in Clermont-Ferrand and Lyon, France, develops off-the-shelf in vivo immunotherapies from banked cancer cell lines that are stimulated to display cancer-associated proteins, tagged with a hapten and inactivated before being given to patients. Its lead candidate STC-1010 is in a first-in-human phase 1/2 trial (BreAK-CRC001) in unresectable locally advanced or metastatic microsatellite-stable colorectal cancer (NCT06934538); the first patients were dosed in September 2025 and the FDA accepted an IND in May 2026. In July 2026 it announced an EUR 11 million (USD 12.6 million) Series A extension, bringing total capital raised since inception to EUR 38 million (USD 43.5 million). Its first registered cancer trial, NCT06934538, was posted on ClinicalTrials.gov in April 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.brenus-pharma.com/"},{"label":"Series A extension release, July 2026","url":"https://www.brenus-pharma.com/articles/brenus-pharma-series-a-extension-new-investors"},{"label":"News","url":"https://www.brenus-pharma.com/news"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06934538"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website and July 2026 release read on 29 October 2026. Founding year not stated on the pages read. The original Series A was not read and is not recorded."],"hq":"Clermont-Ferrand","country":"FR","companyType":"biotech","website":"https://www.brenus-pharma.com/","stage":"startup","investors":[],"funding":[{"round":"Series A extension","year":2026,"amountUsd":12600000,"source":"https://www.brenus-pharma.com/articles/brenus-pharma-series-a-extension-new-investors","note":"EUR 11 million; the release gives the USD figure"}]},"route":"/companies/brenus-pharma/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"trial":[{"id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/"}]}}